Trials / Not Yet Recruiting
Not Yet RecruitingNCT07157553
Effect of Argon Laser Panretinal Photocoagulation on Corneal Endothelial Cell Density .
Effect of Argon Laser Panretinal Photocoagulation on Corneal Endothelial Cell Density Among Patients With Proliferative Diabetic Retinopathy .
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study investigates the effect of argon laser panretinal photocoagulation (PRP) on the corneal endothelial cell density (ECD) in patients with proliferative diabetic retinopathy (PDR) by comparing ECD measurements before and after PRP treatment.
Detailed description
Proliferative diabetic retinopathy (PDR) is characterized by abnormal neovascularization driven by ischemic retinal tissue hypoxia and elevated vascular endothelial growth factor (VEGF) levels. Argon laser retinal photocoagulation (ALRP) is a standard treatment that applies thermal damage to the retinal pigment epithelium, reducing retinal oxygen demand and VEGF production, thereby causing regression of neovascular vessels. However, the laser light must pass through the anterior eye structures, potentially causing thermal and inflammatory damage to tissues such as the corneal endothelium, which is crucial for maintaining corneal transparency. This prospective observational clinical study conducted at Assuit University Hospital evaluates the impact of ALRP on corneal endothelial cell density using specular microscopy before, 1 week, and 1 month after PRP treatment in newly diagnosed PDR patients. Secondary outcomes include changes in cell morphology such as hexagonality and coefficient of variation, indicative of endothelial cell health and stability.
Conditions
Timeline
- Start date
- 2025-10-01
- Primary completion
- 2027-11-30
- Completion
- 2027-12-30
- First posted
- 2025-09-05
- Last updated
- 2025-09-05
Source: ClinicalTrials.gov record NCT07157553. Inclusion in this directory is not an endorsement.